Trump's Decision to Fire BLS Chief Echoes Putin's Strategies
President Donald Trump's firing of the Commissioner of the Bureau of Labor Statistics (BLS) on Friday afternoon just after she delivered a negative jobs report echoes the impulse of many leaders to shoot the messenger. Trump declared, 'I've had issues with the numbers for a long time. We're doing so well. I believe the numbers were phony like they were before the election and there were other times. So I fired her, and I did the right thing.'
While Trump may or may not be friends with Vladimir Putin, he is clearly following the Russian President's HR staffing guidelines to eliminate lieutenants who bring bad news.
As we've documented before, the Federal State Statistics Service (Rosstat) has a long history of manipulating official economic statistics to please Putin, 'bending over backward to correct bad numbers and burying unflattering statistics' under the pressure the Kremlin has exerted to corrupt statistical integrity, especially since Putin's invasion of Ukraine in 2022.
The reliability of official statistics from China has also been brought into question, leading analysts to rely on a wide range of unofficial or proxy indicators to gauge the true state of the Chinese economy. Even China's former Premier, the late Li Keqiang, reportedly confided that he didn't trust official GDP numbers.
Read More: What to Know About the Jobs Report That Led Trump to Fire the Labor Statistics Chief
Like other strongmen, Trump has repeatedly shown a pattern of manipulating data to suit his preferred narrative.
Trump's surprise firing of BLS Commissioner Erika McEntarfer has quickly caught the attention of technical market analysts and economists on both sides of the political spectrum. One side cheers the push to disrupt a slow, bureaucratic federal agency. The other side shouts in dismay over concerns about yet another example of Trump politicizing an apolitical institution. Both responses are warranted.
The accuracy of BLS data has long been questioned as major revisions only come in months later. To their credit, the BLS, in addition to other statistical agencies, has publicly recognized a need to modernize its methodology. Unfortunately, though, the severity of job revisions has worsened since the COVID-19 era, with no successful program to address the issue. The downward revision on Friday of more than 250,000 jobs marked the most significant adjustment since the depths of the pandemic.
However, Trump's accusations against the BLS of rigging the job numbers to make him and the Republican base look bad, and his subsequent firing of McEntarfer based on a belief that BLS revisions were politically motivated, are yet another step closer to authoritarianism. Introducing his latest conspiracy theory, the President went even further by suggesting McEntarfer, whose career spans two decades across Republican and Democratic Administrations, rigged the numbers 'around the 2024 presidential election' in then-Vice President Kamala Harris' favor. Trump conveniently fails to mention that his definition of 'around' was back in August 2024. Recall, the 2024 presidential election was a full three months later in November.
Revisions are not unusual behavior by the BLS. They are a critical part of the natural process for developing an accurate picture of the largest, most dynamic economy in the world. The average size of job revisions since 2003 is not insignificant at 51,000 jobs. And, despite what Trump may want Americans to believe, his tariff policies have created an unprecedented level of uncertainty in the U.S. economy, comparable only to that of 2020, with many economists expecting a recession to follow as a result. Bloomberg reporting has pointed to a possible connection between the severity of negative job revisions and recessionary economic environments.
The BLS has also been subjected to DOGE-led hiring constraints and other resource rescissions. In addition, the Trump Administration's disbanding of the Federal Statistics Advisory Committee in March both eliminated one of the main engines for enhancing agency performance and, perhaps, in what should have been a concerning harbinger, abolished the canary in the data integrity coal mine. Complaints about BLS methods are legitimate, like the reliance on enumerators over scanner data, and deserve attention, but this is not how to fix it.
Read More: What Trump's Win Means for the Economy
This is far from the first time Trump has subordinated statistical integrity to political theater. From crowd sizes to weather forecasts, vote counts to tariff formulas, Trump has discarded facts for fictions that play to his political favor. Trump doesn't just bend the truth—he twists the numbers until they resemble propaganda and then silences those who disagree. As CBS News titan Edward R. Murrow warned 65 years ago: 'To be persuasive, we must be believable. To be believable, we must be credible. To be credible, we must be truthful.'
Contact us at letters@time.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Watch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop
Key Takeaways Novo Nordisk's U.S.-listed shares were slightly higher in recent trading after shedding a third of their value last week, when the company cut its full-year outlook and named a new CEO. The shares had resumed their steep downtrend last week on above-average volume, indicating selling conviction from larger market participants. Investors should watch major support levels on Novo Nordisk's chart around $36 and $29, while also monitoring key overhead areas near $60 and $ Nordisk's (NVO) U.S.-listed shares were up about 2% in recent trading after shedding about a third of their value last week, when the company cut its full-year outlook and named a new CEO, leading Wall Street analysts to downgrade the stock. Since hitting a record high in June last year, Novo Nordisk shares have lost roughly two-thirds of their value, pressured by increasing competition from rival Eli Lilly's (LLY) weight-loss drugs and challenges during trials of the company's next-generation obesity drugs. Below, we take a closer look at Novo Nordisk's weekly chart and use technical analysis to identify major price levels that investors will likely be watching after last week's dramatic sell-off. An Extended Downtrend With last week's drop, Novo Nordisk shares resumed their steep downtrend on above-average trading volume, indicating selling conviction from larger market participants. The sell-off coincided with the relative strength index (RSI) falling to its lowest levels since early May, signaling weakening price momentum, though the indicator neared its oversold threshold, increasing the chances for short-term bounces. It's also worth noting that the 50-week moving average continues to converge toward the 200-week MA, potentially setting the stage for an ominous death cross, a bearish pattern that forecasts lower prices. Let's identify two major support levels on Novo Nordisk's chart worth watching if selling resumes this week and also point out several key overhead areas to monitor during potential recovery efforts. Major Support Levels Worth Watching The first major lower level to watch sits around $36. This area would likely provide support near the upper range of a consolidation period that formed on the chart between October 2020 and April 2021. A more significant move lower could see the shares test lower support at the $29 level. Investors may look for buying opportunities in this area near a horizontal line that connects a range of corresponding price action on the chart between January 2018 and April 2020. Key Overhead Areas to Monitor An initial recovery effort could see the shares climb to overhead resistance around $60. The price may encounter selling pressure in this area near the prominent April trough and April 2022 peak. A more bullish upswing opens the door for a rally toward $78. Investors who have bought Novo Nordisk shares at lower levels may decide to lock in profits in this location near the June peak, which closely aligns with the completion of a pullback in July 2023. The comments, opinions, and analyses expressed on Investopedia are for informational purposes only. Read our warranty and liability disclaimer for more info. As of the date this article was written, the author does not own any of the above securities. Read the original article on Investopedia Sign in to access your portfolio
Yahoo
4 minutes ago
- Yahoo
NCAA Tournament fields to remain at 68 teams in 2026, but future growth is possible
The NCAA men's and women's basketball tournaments will not expand beyond 68 teams in 2026, but future growth remains on the radar. 'Expanding the tournament fields is no longer being contemplated for the 2026 men's and women's basketball championships," Dan Gavitt, NCAA senior vice president of basketball, said in a statement on Monday. "However, the committees will continue conversations on whether to recommend expanding to 72 or 76 teams in advance of the 2027 championships.' NCAA President Charlie Baker has said adding teams could add value to the tournament, and he said the NCAA already has had 'good conversations' with TV partners CBS and Warner Bros., whose deal runs through 2032 at the cost of around $1.1 billion a year. ___ AP college basketball: and
Yahoo
4 minutes ago
- Yahoo
RGTI: Rigetti Shares Jump after Needham hikes target on U.S. quantum momentum
Aug 4 - Rigetti Computing (NASDAQ:RGTI) jumped more than 5% on Monday shortly after Needham raised its price target by $3, signaling fresh momentum in quantum computing. Warning! GuruFocus has detected 3 Warning Signs with RGTI. Analyst Quinn Bolton sees growing buzz around federal programs like DARPA's Quantum Benchmark Initiative (QBI) and the proposed Department of Energy Quantum Leadership Act. He believes those efforts could unlock new research funding and commercial opportunities. Rigetti leads a pack of startups racing to prove quantum machines can outperform classical systems. QBI aims to assess whether quantum devices deliver more value than their cost by 2033. Meanwhile, the DOE bill would allocate $2.5 billion over five years to boost quantum research. Investors weigh the promise of those programs against current realities: most quantum firms still run R&D losses and generate modest revenue. Bolton urges a cautious stance, recommending smaller, speculative positions. Yet his buy rating on Rigetti reflects confidence that government backing could pave the way for breakthroughs and higher stock gains. With Washington pulling out all the stops to keep the U.S. on the leading edge of high-tech, Rigetti advocacy demonstrates the crossroad of policy and private money. This is the place to keep an eye on future legislative actions and DARPA milestones to get new startup catalysts. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
